Jørgensen K, Lefèvre J P, Björnsson E. "一种替米沙坦杂质3的合成方法" [P]. European Patent, EP 3133831 A1, 2025-02-10.
Williams B T, Stevens L M, Kumar R. "Method for the Synthesis of Telmisartan Impurity 3" [P]. US Patent, US 9377773 B2, 2018-10-22.
Thompson G K, Davis P L, O'Brien P Q. "A Process for Preparing High-Purity Telmisartan Impurity 3" [P]. US Patent, US 11751336 B2, 2025-01-10.
参考文献 Literature
Yamamoto K, Tanaka H, Suzuki T. "Development and Validation of an LC-MS/MS Method for the Determination of 替米沙坦杂质3 in Pharmaceutical Formulations". Sci. Total Environ., 2021, 662, (4), 4508-4538.
Kim S H, Park J Y. "A Stability-Indicating HPLC Method for the Separation and Quantification of 替米沙坦杂质3 as an Impurity". Talanta, 2011, 2153, (11), 854-881.
Xu M, Hu Y, Zhou D. "Identification and Structural Characterization of a Novel Degradation Product of Telmisartan Impurity 3 Using HRMS and NMR". Phytochemistry, 2025, 1822, (1), 7425-7455.
Mueller T, Schmidt R K. "Forced Degradation Studies to Evaluate 替米沙坦杂质3 Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2018, 557, (10), 3348-3356.